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Background/Aim. Numerous epidemiological studies have 
shown beneficial effects of cruciferous vegetables consumption 
in cancer chemoprevention. Biologically active compounds of 
different Brassicaceae species with antitumor potential are 
isothiocyanates, present in the form of their precursors – glu- 
cosinolates. The aim of this study was to determine the selec- 
tivity of antiproliferative action of dietary isothiocyanates for 
malignant versus normal cells. Methods. Antiproliferative activ- 
ity of three isothiocyanates abundant in human diet: sulforap- 
hane, benzyl isothiocyanate (BITC) and phenylethyl isothiocy- 
anate, on human cervix carcinoma cell line – HeLa, melanoma 
cell line – Fem-x, and colon cancer cell line – LS 174, and on 
peripheral blood mononuclear cells (PBMC), with or without 
mitogen, were determined by MTT colorimetric assay 72 h af- 
ter their continuous action. Results. All investigated isothiocy- 
anates inhibited the proliferation of HeLa, Fem-x and LS 174 
cells. On all cell lines treated, BITC was the most potent inhibi- 
tor of cell proliferation with half-maximum inhibitory concen- 
tration (IC50) values of 5.04 mmoL m-3 on HeLa cells, 2.76 
mmol m-3 on Fem-x, and 14.30 mmol m-3 on LS 174 cells. An- 
tiproliferative effects on human PBMC were with higher IC50 
than on malignant cells. Indexes of selectivity, calculated as a 
ratio between IC50 values obtained on PBMC and malignant 
cells, were between 1.12 and 16.57, with the highest values ob- 
tained for the action of BITC on melanoma Fem-x cells. Con- 
clusion. Based on its antiproliferative effects on malignant cells, 
as well as the selectivity of the action to malignant vs normal 
cells, benzyl isothiocyanate can be considered as a promising 
candidate in cancer chemoprevention. In general, the safety of 
investigated compounds, in addition to their antitumor potential, 
should be considered as an important criterion in cancer chemo- 
prevention. Screening of selectivity is a plausible approach to the 
evaluation of safety of both natural isothiocyanates and synthe- 
sised analogues of these bioactive compounds. 
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Uvod/Cilj. Brojne epidemiološke studije pokazale su povoljne 
efekte konzumiranja povrća iz familije kupusnjača (Brassicaceae) u 
hemioprevenciji karcinoma. Osnovni biološki aktivni sastojci 
ovog povrća su izotiocijanati, prisutni u obliku prekursora – glu- 
kozinolata. Cilj ovog rada bio je određivanje selektivnosti antip- 
roliferativnog delovanja dijetetskih izotiocijanata na maligne ćelije 
u odnosu na normalne ćelije. Metode. Antiproliferativna aktiv- 
nost tri izotiocijanata zastupljena u ljudskoj ishrani: sulforafana 
(SFN), benzil-izotiocijanata (BITC) i feniletil-izotiocijanata 
(FEITC) na humane maligne ćelijske linije, HeLa, ćelijsku liniju 
karcinoma grlića materice, Fem-x, ćelijsku liniju melanoma, i 
LS 174, ćelijsku liniju karcinoma kolona, kao i na mononukle- 
arne ćelije periferne krvi (MNĆPK), sa ili bez delovanja mito- 
gena, određivana je MTT kalorimetrijskim testom, 72 h nakon 
kontinuiranog delovanja agenasa. Rezultati. Svi ispitivani izo- 
tiocijanati  inhibirali  su  proliferaciju  HeLa,  Fem-x  i  LS  174 
ćelija. Na svim ćelijskim linijama BITC je pokazao najizraženije 
delovanje sa vrednostima polumaksimalne inhibitorne koncen- 
tracije (IC50) od 5.04 mmol m-3  na HeLa ćelijama, 2,76 mmoL 
m-3  na Fem-x i 14,30 mmol m-3  na LS 174 ćelijama. Svi ispiti- 
vani izotiocijanati pokazali su citotoksično delovanje na 
MNĆPK, ali sa višim IC50 vrednostima u odnosu na maligne 
ćelije.  Indeksi  selektivnosti antitumorkog delovanja, izraženi 
kao odnos IC50  vrednosti dobijenih na MNĆPK i malignim 
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ćelijama, bili su između 1,12 i 16,57, sa najvišom vrednosti pri 
delovanju BITC na Fem-x ćelije. Zaključak. Na osnovu an- 
tiproliferativne aktivnosti na maligne ćelije i selektivnosti an- 
tiproliferativnog delovanja na maligne u odnosu na normalne 
ćelije, benzil izotiocijanat se ističe kao perspektivni agens u 
hemioprevenciji karcinoma. Generalno, pored antitumorskog 
delovanja, bezbednost primene ovih jedinjenja treba da pred- 
stavlja važan kriterijum u izboru odgovarajućih izotiocijanata 
za primenu u primarnoj, sekundarnoj i tercijarnoj hemiopre- 
venciji kancera. Ispitivanje selektivnosti predstavlja pogodan 











Numerous epidemiological studies have shown an in- 
verse association between cruciferous vegetable intake and 
risk of different types of cancer 
1–5
. Cruciferous vegetables, 
including broccoli, cauliflower, cabbage, kale, Brussels 
sprouts, water cress, and rocket, among others, are rich sour- 
ces of sulphur containing compounds – glucosinolates (GLs). 
Basic structure of GLs consists of a β-D-thioglucose group, a 
sulfonated oxime group and a side chain derived from diffe- 
rent amino acids. The most abundant source of these plant 
constituents is the family Brassicaceae (Cruciferae) in which 
they were discovered 
6
. Glucosinolates undergo hydrolysis by 
endogenous enzyme myrosinase, to yield glucose, sulphuric 
acid and a molecule of thiocyanates, nitriles, indoles or 
isothiocyanates (ITCs) depending on the side chain in parent 
glucosinolate 
7
.  Myrosinase  accompanies  the  GLs  in  the 
plant tissue, placed in cells separately from GLs and released 
only after the degradation of cell walls (by chopping, 
chewing), thus catalysing the generation of isotiocyanates. 
Intestinal flora also possesses myrosinase activity 
7
. 
Numerous studies, both in vitro and in vivo, have indi- 
cated that the beneficial effects of cruciferous vegetables in 
cancer prevention are the result of the action of ITCs rather 
than the action of their precursors – glucosinolates 
8, 9
. Mec- 
hanisms of anticancer activity of ITCs are numerous 
10
. They 
act both as blocking and suppressing agents able to impede 
initiation, promotion and/or progression of carcinogenesis 
11
. 
Inhibition of carcinogenesis during the initiation stage is 
presumably associated with the modulation of carcinogen 
metabolism, including inhibition of metabolic activation of 
carcinogens by phase I enzymes, coupled with induction of 
detoxifying phase II enzymes 
12
. Inhibition of tumor cell pro- 
liferation is crucial for the inhibitory effects of ITCs on pro- 
motion and progression of carcinogenesis 
13
. Other chemop- 
reventive mechanisms include induction of apoptosis, pre- 
vention of neoangiogenesis, anti-migratory or epigenetic ef- 
fects 
8, 14
. Scientific evidence of antitumor potential of ITCs 
provides  a  rationale  for  their  use  as  chemopreventive 
agents 
15, 16
. Structural differences are the result of different 
side group in a relatively simple chemical structure of ITCs 
and determine specific mechanistic profile of individual mo- 
lecules regarding both antitumor action and their safety 
17
. 
Selectivity of ITCs action towards malignant cells is the ma- 
in criterion for their potential use in primary, secondary or 
tertiary prevention. In general, the balance between efficacy 
and safety (in addition to the costs and practicality of the in- 
tervention) is crucial criterion in the evaluation of chemopre- 
ventive agents regardless the nature and mechanism of their 
action. The balance is shifted to the safety for agents with the 
main role in primary and secondary prevention, while in 
tertiary prevention and therapy efficacy takes the priority 
18
. 
Numerous data have shown that even subtle change in 
chemical structure of the ITCs can have a profound effect on 
their activity and mechanism of action, which have opened a 
wide field of chemical synthesis of ITC analogues with targeted 
effects and increased efficacy 
19–23
. Evaluation of their chemop- 
reventive potential in terms of fine balance between efficacy and 
safety is an important issue for their further use in practice. 
Sulforaphane (SFN), benzyl isothiocyanate (BITC) and 
phenyl ethyl isothiocyanate (PEITC) are ITCs often present in 
human diet (based on the intake of food rich in their precursor 
GLs). Cruciferous vegetables usually contain a large number 
of structurally different GLs. However, SFN, in the form of 
corresponding GL - glucoraphanin, is the major bioactive 
compound in broccoli, BITC in the form of glucotropaeolin, is 
the major bioactive in garden cress, and PEITC in the form of 
GL – gluconasturtiin, is major bioactive of watercress 
24
. 
The aim of this study was to provide data on antiprolife- 
rative action of SFN, BITC and PEITC on a panel of malig- 
nant cell lines in the presence of human sera as a model closer 
to in vivo conditions and with specific focus on the selectivity 
of their antitumor action. Selectivity of antiproliferative action 
towards malignant cells was determined by simultaneous inve- 
stigation of their effects on peripheral blood mononuclear cells 
(PBMC) of healthy volunteers. Applied experiments are pro- 
posed to be used as a plausible and practical screening model 
in the preclinical evaluation of cancer chemopreventive profile 
of natural isothiocyanates and synthesised analogues of these 





Cell cultures and chemicals 
 
Human cervix carcinoma cell line (HeLa), human me- 
lanoma cell line (Fem-x) and human colon cancer cell line 
(LS 174) used in the study were obtained from the American 
Type Culture Collection (Manassas, VA, USA). Cell lines 
were cultured as monolayers in the nutrient medium, i.e. 
RPMI 1640 medium (Sigma–Aldrich, Germany) supplemented 
with L-glutamine (3 moL m
-3
), streptomycin (100 mg L
-1
), pe- 
nicillin (100 IU mL
-1
) and grown at 37°C in atmosphere with 
5% CO2, 95% air and 95% relative humidity. 
Stock solutions of ITCs (Sigma–Aldrich, Germany) were 
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for SFN, 75.4 moL m
-3 
for BITC and 66.8 moL m
-3 
for PE- 
ITC, filtered through Milipore filter 0.22 m and kept at – 20C. 
The whole blood for isolation of sera and PBMC was 
obtained from healthy subjects according to the protocol ap- 
proved by Ethical Committee of the Institute for Oncology 
and Radiology of Serbia (within the project No 175011). The 
study was undertaken according to the Helsinki Declaration 
and all the subjects gave written informed consent prior to 
the enrolment. Human AB+ sera isolated from the whole 
blood of healthy volunteers was pooled and used further ac- 
cording to the protocol. 
 
 
Preparation of peripheral blood mononuclear cells 
 
PBMC were separated from the whole heparinized 
blood of healthy volunteers by gradient centrifugation 
(Lymphoprep, Norway). Cells collected from the interfa- 
ce were washed three times with Haemaccel
® 
(aqueous so- 

















and 35 g L
-1 
gelatin 




Treatment of cell lines 
 
HeLa and  Fem-X cells were seeded at  a  density of 
2,000 cells per well in 96-well plates, in nutrient medium 
supplemented with human serum (a mass fraction of 10%) in 
total volume of 100 L. LS 174 cells were set up at a density 
of 7,000 cells per well and grown similarly. 
The following day, after the adherence, cells were trea- 
ted with ITCs. Briefly, stock solutions were diluted in nutri- 
ent medium supplemented with fresh AB+ human serum (a 
mass fraction of 10%) and 50 µL of the obtained working so- 
lutions was added to the wells. Final concentrations of ITCs 
tested for antiproliferative action on cancer cell lines were 1, 
5, 10, 25, 50 µM. Concentration of DMSO in the cell did not 
exceed 0.17%. Wells with cells treated with DMSO solution 
in nutrient medium, in concentrations equal to the DMSO le- 
vel in wells with 50 µM ITCs (i.e. 0.17% in experiments 
with SFN, 0.07% with PEITC and 0.075 % with BITC) were 
used as controls. It was shown in preliminary experiments 
that in these concentrations DMSO do not influence the pro- 
liferation and the survival of the malignant or normal cells. 
Wells containing ITCs in investigated concentrations but vo- 
id of cells were used as corresponding blanks. 
 
 
Treatment of peripheral blood mononuclear cells 
 
PBMC were seeded in 96-well plates (150,000 cells per 
well) in nutrient medium supplemented with 10% autologous 
human serum, or in supplemented nutrient medium enriched 
with phytohaemaglutinin (PHA; 5 mg L
-1
; Sigma-Aldrich, 
Germany). Stock solutions of ITCs were diluted in nutrient 
medium supplemented with autologous serum (a mass fracti- 
on of 10%) and working solutions was added to the wells. 
Final concentrations of ITCs tested for their action on PBMC 
were 5, 10, 20, 40 and 80 µM. Wells with PBMC and DMSO 
solution in nutrient medium (up to 0.17%) were used as con- 
trols and wells containing ITCs in investigated concentrations 
but void of cells were used as corresponding blanks. The ran- 
ges of ITCs concentrations tested (0–50 µM for experiments 
on cancer cell lines and 0–80 µM on PBMC) were defined ba- 
sed on the preliminary experiments with the highest concentra- 
tion selected as the one that induce the decrease in cell survival 




Determination of cell survival 
 
Cell survival was assayed 72 h after the continuous ITC 
action,   using   MTT   test 
25
.   Briefly,   20   L   of   3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 
Sigma-Aldrich, Germany solution (5 g L
-1 
in phosphate buffe- 
red saline; pH 7,2) was added to each well. Samples were then 
incubated for four hours at 37C in 5% CO2 and humidified air 
atmosphere. Afterwards, 100 L of 10% sodium dodecyl sulfate 
was added to the wells and the plates were kept overnight in the 
CO2 incubator in humidified atmosphere, followed by absorban- 
ce measurements. The absorbance (A) was measured at 570 nm. 
The cell survival (%) was calculated by division of A of sample 
with cells grown in the presence of various concentrations of in- 
vestigated compounds, with control absorbance (Ac) of cells 
grown only in nutrient medium, and multiplied with 100. It 
was implied that A of blank was always subtracted from A of 
corresponding sample with target cells. The half-maximal 
inhibitory concentration (IC50) was determined as a concentra- 
tion of a compound that inhibited cell proliferation by 50% 






All results were presented as mean ± standard deviation 
(SD) of five independent experiments. All experiments are 
performed in triplicates. IC50 values were extracted from do- 
se-response curves for each ITC on each cell type, as a con- 





The results obtained for antiproliferative action of inve- 
stigated compounds show that all investigated ITCs, SFN, 
BITC, and PEITC, significantly inhibited proliferation of 
cultured HeLa, Fem-x and LS 174 cells. Based on IC50 valu- 
es (Table 1) BITC was the most potent inhibitor of cell proli- 
feration in all cell lines treated. The potencies of SFN and 
PEITC were similar. The order of sensitivity of various hu- 
man cancer cell lines to the antiproliferative action of ITCs 
in descending order was: human melanoma, Fem-x cells > 
human cervix adenocarcinoma, HeLa cells > human colon 
carcinoma, LS 174 cells. 
The obtained results show that BITC has the most po- 
tent antiproliferative action compared to SFN and PEITC in 
HeLa and LS 174 cells. Our data from this work also show 
antiproliferative potency of tested ITC also on melanoma Fem– 
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Half-maximal inhibitory concentration (IC50) for the antiproliferative action of 
the investigated compounds on malignant and normal human cells determined by MTT 





SFN BITC PEITC 
HeLa 13.59 ± 1.53 5.04 ± 1.73 12.00 ± 1.97 
Fem-x 6.67 ± 0.73 2.76 ± 0.58 6.22 ± 0.32 
LS 174 16.09 ± 2.44 14.30 ± 5.16 18.23 ± 3.04 
PBMC 29.34 ± 15.3 45.74 ± 18.9 23.41 ± 7.13 
PBMC+PHA 15.30 ± 5.39 21.92 ± 4.63 30.87 ± 6.33 
Data are presented as mean ± standard deviations (SD) of five independent  experiments. 
SFN  –  sulforaphane;  BITC  –  benzyl  isothiocyanate;  PEITC  –  phenyl  ethyl  isothiocyanate; 
PBMC – peripheral blood mononuclear cells; PBMC+PHA – PBMC treated with 
phytohaemagglutinin;   HeLa    –    human    cervix    carcinoma    cell    line;    Fem-x    –    human 
melanoma cell line; LS-174 – human colon cancer cell line; MTT – 3-(4, 5-dimethylthiazol-2-yl) – 
2,5 diphenyltetrazolium bromide. 
 
x cell line. It should be noted that this cell line appears to be the 
most sensitive one. IC50 values for the action of SFN and PEITC 
on Fem-x cells were similar. It should be emphasized that both 
values are similar to the IC50 value of (5.51 ± 0.3 mmoL m
-3
) for 
the action of cisplatin on Fem-x cells that was reported by Pan- 
telić et al. 
26 
in the same experimental design. Even stronger an- 
 
tiproliferative potential of BITC on Fem-x cells compared to the 
action of cisplatin, with twice as lower IC50 value was demons- 
trated in the present study. 
As seen in Figure 1, the shape of dose-response curves 
for the action of ITCs on malignant cells and PBMCs is dif- 
ferent. A characteristic plateau could be observed in the cur- 
 
 
Fig. 1 – Representative graphs showing the survival of HeLa (A), Fem-x (B), LS 174 cells (C), peripheral blood mononuclear 
cells (PBMC, D) and PBMC stimulated with phytohaemagglutinin (E), plotted as a function of concentration (c) of SFN (●), 
BITC (■), and PEITC (▲), determined by MTT test 72 h after the continuous agents action. 
For other abbrevations see under Table 1. 
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SFN BITC PEITC 
2.16 9.07 1.95 
1.12 4.35 2.57 
4.39 16. 57 3.76 
2.28 7.94 4.96 
2.16 3.19 1.28 
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ve for ITCs treated PBMC and PBMC with mitogen in the 
concentration range 0–5 mmoL m
-3
, and a linear dose- 
response correlation with higher doses. Regarding the effects 
on malignant cells, linearity in the response could be obser- 
ved within the whole concentration range. 
The selectivity in the antitumor action was evaluated 
for each ITCs and was expressed as selectivity index (SI), 
calculated as the ratio between IC50 values obtained with 
PBMC or mitogen-treated PBMC and IC50  values for inves- 
tigated ITCs on malignant cells. The values obtained for SI 
are presented in Table 2. 
logical control of tumor growth 
33 
and a possibility to include 
mitogen stimulated cells as a model of normal cells in the 
highly proliferative state. 
PBMC from healthy individuals, stimulated for proliferati- 
on with PHA were similarly sensitive to the cytotoxic action of 
SFN as low sensitive HeLa and LS 174 cells. This is in consent 
with published data which show that after 72 h of incubation 
with 30 mmol m
-3 
of SFN only 16% of T-lymphocytes stimula- 
ted with PHA were viable compared to the control 
34
. It is also in 
accordance with the recently published data that the action of 










IC50 PBMC / IC50 HeLa 
IC50 PBMC+PHA / IC50 HeLa 
IC50 PBMC / IC50 Fem-x 
IC50 PBMC+PHA / IC50 Fem-x 
IC50 PBMC / IC50 LS 174 
SI* 
 IC50 PBMC+PHA / IC50 LS 174  1.12  1.53  1.69   
*SI towards malignant cell line are calculated as the ratio of the half-maximal inhibitory concentration (IC50) 
value for PBMC (or PBMC+PHA) and IC50 value for corresponding cell line. 
SFN – sulforaphane; BITC-benzyl isothiocyanate; PEITC – phenyl ethyl isothiocyanate; PBMC – peripheral 
blood mononuclear cells; PBMC+PHA – PBMC treated with phytohaemagglutinin; HeLa – human cervix 





Investigation of the antiproliferative action of selected 
ITCs reported was performed in the presence of human sera 
(10%), including pooled AB positive sera from healthy do- 
nors used in experiments with malignant cells in culture and 
autologous sera for investigation of antiproliferative effects 
of ITCs on PBMC. As far as authors are aware the antiproli- 
ferative screening of ITCs in the presence of human sera was 
not performed previously. However, it has been shown that 
the presence of human umbilical blood sera has stimulatory 
influence on growth and proliferative capacity of human 
mesenchymal stem cells, without influence on their morpho- 
logical and functional characteristics 
27
. It has been shown 
also that both normal and neoplastic cells of nervous origin, 
cultured in the presence of human sera, have distinct adhe- 
sive characteristics, proliferation capacity and antigen ex- 
pression compared to the same type of cells grown in the 
presence of calf serum 
28
. Accordingly, the proposed experi- 
mental design that includes the presence of human sera with 
putative influence on phenotypic and functional characteris- 
tic of biological models could be considered as better ap- 
proximation of in vivo conditions. However, obtained results 
are in accordance with the previously published data on the 
antiproliferative action of SFN, BITC and PEITC in He- 
La, 
29–31 
as well as in LS 174 cells 
32
. 
Additionally, cell models used for the selectivity asses- 
sment usually include normal cells of the same origin in ad- 
dition to malignant cells 
26  
or PBMCs, as proposed in our 
work. Prioritisation of PBMCs as a model was rationalised 
by important role of PBMC subpopulations in the immuno- 
The  obtained  results  showing  lower  IC50   values  for 
BITC and SFN on PBMC treated with mitogen compared to 
untreated PBMC are in line with previously published da- 
ta 
14
. Action of PEITC characterised with lower IC50  values 
obtained in PBMC than in PBMC treated with mitogen, sug- 
gests different mechanism that needs to be investigated furt- 
her with putative effects on both malignant and non- 
malignant lymphoproliferative diseases. Lower IC50  values 
on PBMC compared to cancer cells was most pronounced for 
BITC as observed also based on the selectivity indexes obta- 
ined that were in a wide range between 3.19 for LS 174 cells 
and 16.57 for Fem-x cells. This is a new result which marks 
BITC as promising cancer suppressive ITC with the highest 
selectivity index among the investigated compounds. 
The observed differences in the antiproliferative poten- 
tial of the investigated ITCs could be at least in part due to 
the differences in kinetics of cellular accumulation. Substan- 
tial accumulation within a cell is a general characteristics of 
the most of the investigated ITCs. However, the kinetics and 
the level of accumulation strongly depend on the nature of 
particular ITCs, incubation temperature and glutathione le- 
vels in the cell 
36
. It was shown on Hepa 1clc7 liver cells that 
BITC accumulation is a fast process with maximum concen- 
trations reached 30 minutes after the exposure, followed by 
rapid decline in intracellular concentration leading to com- 
plete clearance after 24 h 
36
. Contrary to BITC, very slow in- 
tracellular accumulation was observed in cells exposed to the 
same concentrations of SFN with maximum levels reached 
12 h after the exposure, followed by the slow decline with 
half of maximum levels detected at 24 h. This was confirmed 
in other cell lines treated with the same concentrations of bi- 
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oactives during 30 minutes. Surprisingly, intracellular levels 
of BITC were up to 3 times higher compared to the levels of 
SFN 
36
. The capacity of ITCs to induce antioxidant enzymes 
activity has shown the inverse correlation with the accumulati- 
on kinetics and ITCs levels observed 24 h after the exposure, 
with SFN highlighted as the best inducer of their activity. 
Contrary to the influence on antioxidant enzymes activity, ki- 
netics of the intracellular transfer was shown to be in direct 
correlation with the antiproliferative capacities of different 
ITCs. In a panel of malignant cells of different origin (HL60S, 
8662/S, MCF-7, HepG2, HT-29, HaCaT) IC50 values obtained 
after 72 h of continuous exposure to BITC and PEITC were 
similar to the IC50 values obtained after the same period, i.e. 72 
h that combines 3 h of direct exposure to ITCs followed by 
washings  and  subsequent  69  h  long  incubation  without 
ITCs 
36
. The results obtained for SFN were different in IC50 
values after 72 h of exposure to SFN 10 times lower compared 
to  the  3h-long  exposure  followed  by  69  h  of  incubation 
without ITCs 
36
. However, after short exposure to the same 
concentrations of ITCs, BITC accumulation in cells, levels of 
reactive  oxygen  species  and  antiproliferative  capacity  are 
much higher than in SFN treated cells 
37
. The observed diffe- 
rences, mostly due to different side chains influencing their 
lipophilicity have major effects on intracellular action of ITCs. 
Within a cell all ITCs react directly via carbon atom of the – 
N=C=S group with the cysteine sulfhydryl groups of glutathi- 
one (GSH) and proteins. The side chains generally play 
secondary role, mainly by influencing the electrophilicity of 
the –N=C=S group and steric effects 
38
. With greater ITCs 
influx and subsequent GSH depletion, cells are more sensitive 
to the effects of intracellular reactive oxygen species (ROS). 
On the contrary, slower influx and consequent slow decrease 
on GSH level could act as a signal for glutathione-S- 
transferase activation, resulting in higher GSH levels 
38
. Mali- 
gnant phenotype is characterised by high levels of oxidative 
stress, mainly due to high levels of ROS and disturbed ratio 
between reduced and oxidised form of GSH 
39
. The persistent 
oxidative stress in cancer cells sensitizes them to stress or 
apoptotic effects of anticancer drugs, which often generate 
ROS, because they are already near a threshold for tolerating 
ROS. It is not the case with normal cells, with lower producti- 
on of H2O2 
40
. It seems that the fate of cancer cells to survive 
the  effects of  ITC depends on  constitutive levels of  ROS 
and/or glutathione, the type, dose and accumulation kinetics of 
ITC the cells were exposed to, resulting in the difference in 
sensitivity of different cells types and the difference in ITCs 
selectivity regarding their antiproliferative action. 
It has been shown previously that chemopreventive ac- 
tion of SFN, as the strongest inhibitor of phase I enzymes 
and inductor of phase II enzymes in this group of bioactives, 
is mediated mainly by the modulation of carcinogen metabo- 
lism 
15
. Accordingly, SFN is the major ITC highlighted for 
the use in primary prevention at low dietary relevant doses, 
via its major dietary sources, including broccoli. However, 
the selectivity indexes for the action of SFN are lower com- 
pared to other investigated ITCs suggesting that SFN at hig- 
her doses (as isolated molecule or in enriched extracts) could 
affect proliferation of immunocompetent cells. It should be 
noted that the obtained results rationalize further investigati- 
on of putative beneficial effects of SFN on the suppression of 
limphoproliferative or autoimmune diseases. 
Compared to SFN and PEITC, BITC has shown better 
characteristics as chemopreventive agent acting on the proli- 
feration of cancer cells. The pronounced selectivity in anti- 
tumor action of this compound, by comparison of its effects 
on malignant cells and PBMC, favors this particular ITC for 
the use as cancer suppressive chemopreventive agent. BITC 
is a major ITC of garden cress, and it is not present in broc- 
coli or in many other dietary sources of glucosinolates and 
isothiocyanates 
24
. Thus, in addition to its beneficial effects 
the distribution in dietary plants should be taken into account 
in  evidence-based  personalised  nutrition  recommendation 
and  the  use  of  dietary  sources of  BITC  in  secondary or 
tertiary chemoprevention. Other dietary sources of glucotro- 
peolin and BITC that are not part of westernised diet should 
be promoted to provide higher intake of this bioactive com- 





Numerous biological effects of ITCs suggest their active 
role in dietary prevention of malignant and other chronic dise- 
ases that represent major burden to health worldwide. Our data 
contribute to the rationale for future comprehensive studies 
that could eventually lead to more specific dietary guidance 
and recommendations for increased intake of vegetables conta- 
ining particular glucosinolates and ITCs, targeted to the speci- 
fic populations such are cancer patients or subjects at high 
cancer risk. Further research and conclusions based on human 
intervention trials are needed to provide additional scientific 
evidence for the beneficial effects of long-term intake of BITC 
or its dietary sources in cancer patients, as agent in tertiary 
chemoprevention or even as a complementary therapeutic. 
ITCs are also considered as a good starting point for synthesis 
of functional analogues that will enhance their biological 
activity. However, the critical assessment of their safety sho- 
uld be included in the evaluation of their potential use in 
primary, secondary and tertiary prevention of cancer, as a part 
of balanced diet, functional component of functional foods and 
dietary supplements, chemopreventive agents and therapeutics. 
Screening of selectivity by applying a model presented in this 
work is a plausible approach for the preclinical evaluation of 
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